124 related articles for article (PubMed ID: 840339)
1. Human malignant melanoma cells: morphological and immunological variations.
Hakim AA
Neoplasma; 1977; 24(1):81-99. PubMed ID: 840339
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte-mediated cytotoxicity on human tumor cells in vitro.
Schwenke H; Schönfelder M
Arch Geschwulstforsch; 1975; 45(8):802-9. PubMed ID: 1241765
[TBL] [Abstract][Full Text] [Related]
3. Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3).
Peter HH; Pavie-Fischer J; Fridman WH; Aubert C; Cesarini JP; Roubin R; Kourilsky FM
J Immunol; 1975 Aug; 115(2):539-48. PubMed ID: 1171141
[TBL] [Abstract][Full Text] [Related]
4. Production of antisera with specificity for malignant melanoma and human fetal skin.
Fritze D; Kern DH; Drogemuller CR; Pilch YH
Cancer Res; 1976 Feb; 36(2 Pt 1):458-66. PubMed ID: 56991
[TBL] [Abstract][Full Text] [Related]
5. Problems in the clinical use of the microcytotoxicity assay for measuring cell-mediated immunity to tumor cells.
Heppner G; Henry E; Stolbach L; Cummings F; McDonough E; Calabresi P
Cancer Res; 1975 Aug; 35(8):1931-7. PubMed ID: 1149017
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a chimpanzee anti-human melanoma antiserum.
Stuhlmiller GM; Seigler HF
Cancer Res; 1975 Aug; 35(8):2132-7. PubMed ID: 1149027
[TBL] [Abstract][Full Text] [Related]
7. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
Takahashi T; Irie RF; Morton DL; Hoon DS
Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
[TBL] [Abstract][Full Text] [Related]
8. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
10. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
[TBL] [Abstract][Full Text] [Related]
11. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression.
Mukherji B; Nashed AL; Guha A; Ergin MT
J Immunol; 1986 Mar; 136(5):1893-8. PubMed ID: 2419419
[TBL] [Abstract][Full Text] [Related]
13. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
14. Pokeweed mitogen-stimulated human lymphocytes fused to LICR-2 (HMY2) generate human-human hybridomas producing monoclonal IgG antibodies reactive to human breast carcinoma and malignant melanoma.
Martin RF; Kisor R; Schroer D; Eichler G; Filaccio ML
Hum Antibodies Hybridomas; 1990; 1(3):154-9. PubMed ID: 2103359
[TBL] [Abstract][Full Text] [Related]
15. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
16. Immunological studies on malignant melanomas of man.
Romsdahl MM; Cox IS
Yale J Biol Med; 1973 Dec; 46(5):693-701. PubMed ID: 4205125
[No Abstract] [Full Text] [Related]
17. In vitro immunization of human B lymphocytes with cultured melanoma cells (SK-MEL 28).
Zhang XM; Borrebaeck CA
Hum Antibodies Hybridomas; 1990; 1(1):42-6. PubMed ID: 1966473
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin-like mediator.
Peter HH; Eife RF; Kalden JR
J Immunol; 1976 Feb; 116(2):342-8. PubMed ID: 1082453
[TBL] [Abstract][Full Text] [Related]
20. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
